i.Mune™ NEO* is a molecular test for relative quantification (%) of human CD3+T-, B-, NK-cells, TSDR+ regulatory T-cells and neutrophils in dried blood spot (DBS) samples.
i.Mune™ NEO* is suitable for epigenetic quantification of:
TSDR = Treg Spezifische De-methylierte Region
A cohort of 250 apparently healthy newborns and 24 confirmed SCID and XLA cases was analyzed using epigenetic immune cell quantification of T-, B- and NK Zellen in dried blood spot samples1)
23 out of 24 confirmed SCID or XLA cases were correclty identified using the epigenetic immune cell quantification method.
Using combined TREC/KREC Analysis, 22 out of 24 cases were correctly identified1)
Epigenetic quantification of regulatory T-cells (Treg) shows quantitative dysregulation in patients and newborns with IPEX Syndrome2)
Quantitative changes in neutrophils are detected in newborns with severe congenital neutropenia (SCN) using epigenetic immune cell quantification. 1)
Possible applications**:
*i.Mune TBNK is for research use, only and has not been registered as an IVD product and has not been approved or cleared by a regulatory authority.
**Die above possible clinical applications are currently tested in several studies